MCID: UND005
MIFTS: 58

Undifferentiated Pleomorphic Sarcoma

Categories: Rare diseases, Bone diseases, Cancer diseases

Aliases & Classifications for Undifferentiated Pleomorphic Sarcoma

MalaCards integrated aliases for Undifferentiated Pleomorphic Sarcoma:

Name: Undifferentiated Pleomorphic Sarcoma 53 59
Malignant Fibrous Histiocytoma 53 73
Ups 53 59
Malignant Fibrohistiocytic Tumors 53

Characteristics:

Orphanet epidemiological data:

59
undifferentiated pleomorphic sarcoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/1000000 (United States); Age of onset: Adolescent,Adult,Childhood,Elderly; Age of death: any age;

Classifications:

Orphanet: 59  
Rare bone diseases


External Ids:

Orphanet 59 ORPHA2023
MESH via Orphanet 45 D051677
UMLS via Orphanet 74 C0334463
ICD10 via Orphanet 34 C49.9

Summaries for Undifferentiated Pleomorphic Sarcoma

NIH Rare Diseases : 53 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 2023Disease definitionUndifferentiated pleomorphic sarcoma (UPS) is an aggressive sarcoma of soft tissues or bone that can arise from any part of the body, clinically presenting as swelling, mass, pain, pathological fracture and occasional systemic features and is characterized by high local recurrence and significant metastasis.EpidemiologyUPS ranks the 4th most common soft tissue sarcoma with a slight male preponderance. The incidence has been evaluated to be close to 0.8-1 new case per 100000 per year in one European series.Clinical descriptionThe tumor arises most commonly during the sixth and seventh decades of life. The most common sites of involvement include lower extremities (mainly thigh) followed by upper arms, retroperitoneum, viscera, head and neck (in childhood). Primary osseous UPS most commonly occurs in distal femur, proximal tibia, proximal femur and humerus. Patients may present pain, swelling / mass and pathological fractures. In the skin, UPS presents as a relatively painless, rapidly enlarging nodule. Anorexia, malaise, fever and weight loss are present in retroperitoneal and inflammatory forms of UPS. Most UPS recur locally; distant metastases are common (the most frequent is lung). Regional metastases are rare.EtiologyUPS is thought to be derived from a primitive mesenchymal cell capable of differentiating into histiocytes, fibroblasts, myofibroblasts and osteoclasts. The etiology of the tumor remains unknown. Prior radiation therapy is a likely risk factor in some cases.Diagnostic methodsAny tumor mass over 5 cm is suspected to be a sarcoma. Magnetic resonance imaging (MRI) is the imaging method of choice for limbs and shows a high signal on T2 weighted images. Histology of biopsy specimen prior to any treatment is crucial to reach diagnosis and shows pleomorphic spindle cell population with large atypical cells frequently exhibiting numerous irregular mitotic figures, associated regions of hemorrhage and necrosis, associated lymphohistiocytic infiltrate and invasion of dermis. Immunohistochemical staining is negative for S-100, HMB-45, CD34 and cytokeratin which assists in ruling out other soft tissue tumors. Most cases previously diagnosed as malignant fibrous histiocytoma have been reclassified into other histological types of sarcoma.Differential diagnosisWhen occurring in skin, UPS is difficult to differentiate from atypical fibroxanthoma or dermatofibrosarcoma protuberans (see this term). Histological differential diagnoses include leiomyosarcoma, rhabdomyosarcoma, lymphoma, and melanoma (see these terms).Management and treatmentUPS should be referred to an expert/ reference center for primary biopsy, expert pathology review, and multidisciplinary treatment. Immediate surgery of a mass without knowledge of its histological nature is strongly discouraged because it is associated with an increased risk of death due to inappropriate resection and increased risk of relapse. UPS is best treated by wide surgical excision. Sometimes amputation may be necessary to remove the whole lesion. Adjuvant radiotherapy is given for high-grade, large (>5 cm), deep-seated tumors, in limb sparing surgeries and when negative margins are not obtained. For non-operable sarcomas, primary radiation therapy could be an option, but usually doxorubicin containing regimens are preferred options in first-line setting for locally irresectable and/or metastatic lesions. Chemotherapy (CHT) with ifosfamide, trabectedin, dacarbazine, pazopanib have demonstrated efficacy in UPS and are registered and available in most European Union countries.PrognosisA 5-year overall survival rate of 48% has been reported for patients with head and neck tumors versus 77% for patients with tumors arising on the trunk and extremities. The childhood variant appears have better prognosis.Visit the Orphanet disease page for more resources.

MalaCards based summary : Undifferentiated Pleomorphic Sarcoma, also known as malignant fibrous histiocytoma, is related to desmoid tumor and gastrointestinal stromal tumor. An important gene associated with Undifferentiated Pleomorphic Sarcoma is MET (MET Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are HIV Life Cycle and Class I MHC mediated antigen processing and presentation. The drugs Doxorubicin and Dacarbazine have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and skin, and related phenotypes are abnormality of the peritoneum and abnormality of the lower limb

Wikipedia : 76 Undifferentiated pleomorphic sarcoma (UPS), previously malignant fibrous histiocytoma (abbreviated MFH),... more...

Related Diseases for Undifferentiated Pleomorphic Sarcoma

Diseases related to Undifferentiated Pleomorphic Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 190)
# Related Disease Score Top Affiliating Genes
1 desmoid tumor 30.8 KIT PDGFRA
2 gastrointestinal stromal tumor 30.1 KIT KRAS PDGFRA
3 diaphyseal medullary stenosis with malignant fibrous histiocytoma 12.8
4 malignant fibrous histiocytoma of bone 12.5
5 ichthyosis tapered fingers midline groove up 11.9
6 kabuki syndrome 1 11.9
7 malignant fibroxanthoma 11.6
8 porphyria, acute intermittent 11.5
9 urticaria pigmentosa 11.2
10 frontotemporal lobar degeneration with tdp43 inclusions, grn-related 11.2
11 peripheral vascular disease 11.0
12 carpal tunnel syndrome 10.9
13 wilson disease 10.9
14 muscular dystrophy, duchenne type 10.9
15 gout 10.9
16 hemochromatosis, type 1 10.9
17 cystic fibrosis 10.9
18 lung cancer 10.9
19 psoriasis 10.9
20 phenylketonuria 10.9
21 esophageal cancer 10.9
22 pulmonary embolism 10.9
23 narcolepsy 10.9
24 hernia, hiatus 10.9
25 refractive error 10.9
26 glaucoma-related pigment dispersion syndrome 10.9
27 rippling muscle disease 2 10.9
28 alzheimer disease 10.9
29 sarcoma 10.9
30 breast cancer 10.8
31 bipolar disorder 10.8
32 ulcerative colitis 10.8
33 coronary heart disease 1 10.8
34 amyloidosis 10.8
35 spinal cord injury 10.8
36 sinusitis 10.8
37 congenital toxoplasmosis 10.8
38 acute promyelocytic leukemia 10.8
39 rare adenocarcinoma of the breast 10.8 KRAS PIK3CA
40 hyperthyroidism 10.8
41 primary biliary cholangitis 10.8
42 liver cirrhosis 10.8
43 angina pectoris 10.8
44 west syndrome 10.8
45 poliomyelitis 10.8
46 intrahepatic cholestasis 10.8
47 testicular seminoma 10.8
48 al amyloidosis 10.8
49 cystinosis 10.8
50 langerhans cell histiocytosis 10.8

Graphical network of the top 20 diseases related to Undifferentiated Pleomorphic Sarcoma:



Diseases related to Undifferentiated Pleomorphic Sarcoma

Symptoms & Phenotypes for Undifferentiated Pleomorphic Sarcoma

Human phenotypes related to Undifferentiated Pleomorphic Sarcoma:

59 32 (show all 10)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormality of the peritoneum 59 32 hallmark (90%) Very frequent (99-80%) HP:0002585
2 abnormality of the lower limb 59 32 hallmark (90%) Very frequent (99-80%) HP:0002814
3 soft tissue sarcoma 59 32 hallmark (90%) Very frequent (99-80%) HP:0030448
4 abnormal test result 59 32 hallmark (90%) Very frequent (99-80%) HP:0500014
5 fever 59 32 frequent (33%) Frequent (79-30%) HP:0001945
6 abnormality of the musculature 59 32 frequent (33%) Frequent (79-30%) HP:0003011
7 weight loss 59 32 occasional (7.5%) Occasional (29-5%) HP:0001824
8 anorexia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002039
9 abnormality of the upper limb 59 32 occasional (7.5%) Occasional (29-5%) HP:0002817
10 fatigue 59 32 occasional (7.5%) Occasional (29-5%) HP:0012378

GenomeRNAi Phenotypes related to Undifferentiated Pleomorphic Sarcoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.62 PIK3CA KRAS
2 Decreased viability GR00106-A-0 9.62 KRAS
3 Decreased viability GR00173-A 9.62 PDGFRA
4 Decreased viability GR00221-A-1 9.62 PDGFRA PIK3CA KIT KRAS
5 Decreased viability GR00221-A-2 9.62 PIK3CA KRAS
6 Decreased viability GR00221-A-3 9.62 PDGFRA
7 Decreased viability GR00221-A-4 9.62 PDGFRA PIK3CA
8 Decreased viability GR00301-A 9.62 KIT KRAS
9 Decreased viability GR00381-A-1 9.62 KRAS
10 Decreased viability GR00402-S-2 9.62 PDGFRA PIK3CA KIT KRAS

MGI Mouse Phenotypes related to Undifferentiated Pleomorphic Sarcoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.13 KIT KRAS MET PDGFRA PIK3CA PRDM10
2 mortality/aging MP:0010768 10.07 CD74 EZR IDH1 KIT KRAS MET
3 immune system MP:0005387 10.06 CD74 EZR IDH1 KIT KRAS MET
4 digestive/alimentary MP:0005381 9.93 EZR KIT KRAS MET PDGFRA STAT3
5 muscle MP:0005369 9.8 KIT KRAS MET PDGFRA PIK3CA STAT3
6 neoplasm MP:0002006 9.8 IDH2 KIT KRAS MET PDGFRA PIK3CA
7 no phenotypic analysis MP:0003012 9.63 MLANA PDGFRA PIK3CA KIT KRAS MET
8 respiratory system MP:0005388 9.43 IDH1 KIT KRAS MET PDGFRA STAT3
9 skeleton MP:0005390 9.17 CD74 IDH1 KIT KRAS PDGFRA PIK3CA

Drugs & Therapeutics for Undifferentiated Pleomorphic Sarcoma

Drugs for Undifferentiated Pleomorphic Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 100)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
2
Dacarbazine Approved, Investigational Phase 3,Phase 2 4342-03-4 5351166
3
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 51-75-2 4033
4
Ifosfamide Approved Phase 3,Phase 2,Phase 1,Not Applicable 3778-73-2 3690
5
Lenograstim Approved, Investigational Phase 3 135968-09-1
6
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
7
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
8
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
9
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
10
Dactinomycin Approved, Investigational Phase 3 50-76-0 2019 457193
11
Epirubicin Approved Phase 3 56420-45-2 41867
12
Trabectedin Approved, Investigational Phase 3,Phase 2 114899-77-3 108150
13
Gemcitabine Approved Phase 3,Phase 1,Phase 2 95058-81-4 60750
14
Docetaxel Approved, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124
15
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1,Not Applicable 31703
16
Isophosphamide mustard Phase 3,Phase 2,Phase 1,Not Applicable 0
17 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
18 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
19 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
20 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
21 Anti-Infective Agents Phase 3,Phase 2,Phase 1
22 Antiviral Agents Phase 3,Phase 2,Phase 1
23 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
24 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
25 Etoposide phosphate Phase 3,Phase 2
26 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
27 Antirheumatic Agents Phase 3,Phase 2,Phase 1
28 Antimitotic Agents Phase 3,Phase 2,Phase 1
29 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
30 Antimetabolites Phase 3,Phase 1,Phase 2
31 Antimetabolites, Antineoplastic Phase 3,Phase 1,Phase 2
32
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
33
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
34
Indinavir Approved Phase 2 150378-17-9 5362440
35
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
36
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2,Phase 2 22916-47-8 4189
37
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
38
Everolimus Approved Phase 1, Phase 2,Phase 2 159351-69-6 6442177
39
Sirolimus Approved, Investigational Phase 1, Phase 2,Phase 2 53123-88-9 5284616 6436030 46835353
40
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
41
Pembrolizumab Approved Phase 1, Phase 2,Phase 2 1374853-91-4
42
nivolumab Approved Phase 2,Phase 1 946414-94-4
43
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
44
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
45
Bevacizumab Approved, Investigational Phase 2 216974-75-3
46
Nicotinamide Approved, Investigational, Nutraceutical Phase 2 98-92-0 936
47
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
48
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
49
leucovorin Approved, Nutraceutical Phase 2 58-05-9 143 6006
50 Exatecan Investigational Phase 2 171335-80-1

Interventional clinical trials:

(show top 50) (show all 62)
# Name Status NCT ID Phase Drugs
1 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
3 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
4 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
5 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
6 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
7 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
8 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
9 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
10 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3 epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
11 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
12 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Recruiting NCT01344018 Phase 3
13 A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Active, not recruiting NCT02451943 Phase 3 Olaratumab;Doxorubicin;Placebo
14 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
15 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
16 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
17 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
18 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
19 Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Completed NCT00400569 Phase 2 Sunitinib Malate (SU011248)
20 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2 imatinib mesylate
21 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
22 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
23 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
24 Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung Completed NCT00503295 Phase 2
25 Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma Completed NCT00085475 Phase 2 imatinib mesylate
26 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
27 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
28 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
29 Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma Completed NCT00949325 Phase 1, Phase 2 temsirolimus (Torisel) plus liposomal doxorubicin (Doxil)
30 Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00064220 Phase 2 soblidotin
31 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
32 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
33 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
34 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
35 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2 brostallicin
36 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2 exatecan mesylate
37 Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma Recruiting NCT03123276 Phase 1, Phase 2 Pembrolizumab;Gemcitabine
38 Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma Recruiting NCT03307616 Phase 2 Nivolumab;Ipilimumab
39 Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma Recruiting NCT03190174 Phase 1, Phase 2 Nab-Rapamycin
40 Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy Recruiting NCT03474094 Phase 2
41 Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes Recruiting NCT02815995 Phase 2 Durvalumab;Tremelimumab
42 Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Recruiting NCT02601209 Phase 1, Phase 2 Pazopanib Hydrochloride;Sapanisertib
43 A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma Recruiting NCT03414229 Phase 2 Epacadostat;Pembrolizumab
44 Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin;Olaratumab
45 Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery Recruiting NCT02500797 Phase 2
46 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
47 A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma Active, not recruiting NCT00667342 Phase 2 Cisplatin;Doxorubicin;Methotrexate;Ifosfamide;etoposide
48 Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery Suspended NCT02923778 Phase 2
49 Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) Terminated NCT01418001 Phase 1, Phase 2 Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination
50 Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue Sarcoma Terminated NCT00740597 Phase 2

Search NIH Clinical Center for Undifferentiated Pleomorphic Sarcoma

Genetic Tests for Undifferentiated Pleomorphic Sarcoma

Anatomical Context for Undifferentiated Pleomorphic Sarcoma

MalaCards organs/tissues related to Undifferentiated Pleomorphic Sarcoma:

41
Bone, Lung, Skin, Testes, Liver, Endothelial, Brain

Publications for Undifferentiated Pleomorphic Sarcoma

Articles related to Undifferentiated Pleomorphic Sarcoma:

(show top 50) (show all 88)
# Title Authors Year
1
Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. ( 29308306 )
2018
2
Establishment and proteomic characterization of a novel cell line, NCC-UPS2-C1, derived from a patient with undifferentiated pleomorphic sarcoma. ( 29359268 )
2018
3
Esophageal carcinosarcoma comprised of minimally invasive squamous cell carcinoma and undifferentiated pleomorphic sarcoma: A collision cancer? ( 29934989 )
2018
4
Undifferentiated pleomorphic sarcoma. ( 29641724 )
2018
5
Undifferentiated Pleomorphic Sarcoma of Pancreas: A Case Report and Review of the Literature for the Last Updates. ( 29955231 )
2018
6
Extended right hepatectomy with inferior vena cava replacement as an aggressive rescue procedure for threatening venous outflow occlusion in a pretreated undifferentiated pleomorphic sarcoma of the liver. ( 29366308 )
2018
7
Undifferentiated Pleomorphic Sarcoma: Factors Predictive of Adverse Outcomes. ( 29787841 )
2018
8
Biology and Management of Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, and Malignant Peripheral Nerve Sheath Tumors: State of the Art and Perspectives. ( 29220302 )
2018
9
Cardiac Undifferentiated Pleomorphic Sarcoma Mimicking Left Atrial Myxoma. ( 29551281 )
2018
10
Recurrent Acute Myocardial Infarction Caused by Intra-cardiac Metastatic Undifferentiated Pleomorphic Sarcoma during Cancer Treatment. ( 29629023 )
2018
11
Undifferentiated pleomorphic sarcoma of the orbital region: a case report. ( 29846420 )
2018
12
Undifferentiated Pleomorphic Sarcoma after Pirfenidone Use: A Case Report. ( 29702057 )
2018
13
Mouse genetic background influences whether <i>Hras<sup>G12V</sup></i> expression plus <i>Cdkn2a</i> knockdown causes angiosarcoma or undifferentiated pleomorphic sarcoma. ( 29731980 )
2018
14
Primary undifferentiated pleomorphic sarcoma of the thyroid: A case report and review of the literature. ( 29443775 )
2018
15
Aggressively progressing primary undifferentiated pleomorphic sarcoma in the eyelid: A case report and review of the literature. ( 28471957 )
2017
16
Cardiac undifferentiated pleomorphic sarcoma incidentally diagnosed during mitral valve replacement. ( 28127801 )
2017
17
Radiation therapy for recurrent cardiac undifferentiated pleomorphic sarcoma after three operations. ( 28434140 )
2017
18
Undifferentiated pleomorphic sarcoma of the neck - A case report. ( 29031178 )
2017
19
PDGFRa amplification in multiple skin lesions of undifferentiated pleomorphic sarcoma: A clue for intimal sarcoma metastases. ( 28105789 )
2017
20
Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma. ( 29099264 )
2017
21
Conception and Management of a Poorly Understood Spectrum of Dermatologic Neoplasms: Atypical Fibroxanthoma, Pleomorphic Dermal Sarcoma, and Undifferentiated Pleomorphic Sarcoma. ( 28762020 )
2017
22
Radiation-induced undifferentiated pleomorphic sarcoma of the heart: A case report. ( 29305110 )
2017
23
Undifferentiated pleomorphic sarcoma: indolent, tail-like recurrence of a high-grade tumor. ( 28932893 )
2017
24
Undifferentiated Pleomorphic Sarcoma and the Importance of Considering the Oncogenic and Immune-Suppressant Role of the Human T-Cell Lymphotropic Virus Type 1: A Case Report. ( 28596939 )
2017
25
miR-152 down-regulation is associated with MET up-regulation in leiomyosarcoma and undifferentiated pleomorphic sarcoma. ( 27900663 )
2017
26
Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma. ( 28891048 )
2017
27
Primary Culture of Undifferentiated Pleomorphic Sarcoma: Molecular Characterization and Response to Anticancer Agents. ( 29292724 )
2017
28
Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone. ( 28552826 )
2017
29
Primary Undifferentiated Pleomorphic Sarcoma of the Penis. ( 29230132 )
2017
30
LN2, CD10, and Ezrin Do Not Distinguish Between Atypical Fibroxanthoma and Undifferentiated Pleomorphic Sarcoma or Predict Clinical Outcome. ( 28079637 )
2017
31
A Rare Cause of Dyspnea: Undifferentiated Pleomorphic Sarcoma in the Left Atrium. ( 29118888 )
2017
32
Undifferentiated pleomorphic sarcoma of the skin - a UV-induced occupational skin disease? ( 28220622 )
2017
33
A novel anionic-phosphate-platinum complex effectively targets an undifferentiated pleomorphic sarcoma better than cisplatinum and doxorubicin in a patient-derived orthotopic xenograft (PDOX). ( 28968995 )
2017
34
Efficacy In Vitro of Caffeine and Valproic Acid on Patient-Derived Undifferentiated Pleomorphic Sarcoma and Rhabdomyosarcoma Cell Lines. ( 28739691 )
2017
35
A Trp53fl/flPtenfl/fl mouse model of undifferentiated pleomorphic sarcoma mediated by adeno-Cre injection and in vivo bioluminescence imaging. ( 28841687 )
2017
36
A case of a resected benign myxoma-like hemorrhagic cyst, which later recurred as undifferentiated pleomorphic sarcoma in the left atrium. ( 28422827 )
2017
37
Corrigendum to &amp;quot;Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone&amp;quot; [Hum Pathol 2017;65:239-46]. ( 29146074 )
2017
38
Analysis of Clinical and Molecular Factors Impacting Oncologic Outcomes in Undifferentiated Pleomorphic Sarcoma. ( 26847678 )
2016
39
Intraventricular Undifferentiated Pleomorphic Sarcoma: A Case Report. ( 28003940 )
2016
40
Xenograft models for undifferentiated pleomorphic sarcoma not otherwise specified are essential for preclinical testing of therapeutic agents. ( 27446424 )
2016
41
Radiation-induced undifferentiated pleomorphic sarcoma after radiation therapy for a desmoid tumour. ( 26725422 )
2016
42
RAS/MAPK pathway hyperactivation determines poor prognosis in undifferentiated pleomorphic sarcomas. ( 26479291 )
2016
43
Primary undifferentiated pleomorphic sarcoma of the breast in a young female: a case report. ( 27421259 )
2016
44
Phosphorylation of STAT3 in Undifferentiated Pleomorphic Sarcoma Is Correlated with a Favorable Prognosis. ( 27652596 )
2016
45
Undifferentiated Pleomorphic Sarcoma Presenting as Abdominal Pain with a Pulsatile Mass. ( 27563479 )
2016
46
An unusual cause of life-threatening right-sided heart failure: undifferentiated pleomorphic sarcoma in the right ventricular outflow tract. ( 26670651 )
2016
47
Undifferentiated pleomorphic sarcoma of the vocal fold. ( 27929601 )
2016
48
Tail of Superficial Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma After Preoperative Radiotherapy. ( 27127141 )
2016
49
High-grade undifferentiated pleomorphic sarcoma of the pelvis: A case report and review of literature. ( 27453666 )
2016
50
Optimal Percent Myxoid Component to Predict Outcome in High-Grade Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma. ( 26759307 )
2016

Variations for Undifferentiated Pleomorphic Sarcoma

Cosmic variations for Undifferentiated Pleomorphic Sarcoma:

9
(show top 50) (show all 232)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM10654 TP53 soft tissue,bone,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.637C>T p.R213* 17:7674894-7674894 12
2 COSM44151 TP53 soft tissue,lung,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.535C>A p.H179N 17:7675077-7675077 12
3 COSM10660 TP53 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.818G>A p.R273H 17:7673802-7673802 12
4 COSM6911821 SUFU soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.780G>T p.E260D 10:102597163-102597163 12
5 COSM5564171 PTPRT soft tissue,bone,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.3424C>T p.R1142W 20:42106818-42106818 12
6 COSM6933928 PTPRD soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.5686T>C p.S1896P 9:8317927-8317927 12
7 COSM5154 PTEN soft tissue,retroperitoneum,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.697C>T p.R233* 10:87957915-87957915 12
8 COSM6920563 PIK3CA soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.168C>A p.Y56* 3:179198993-179198993 12
9 COSM6911819 NOTCH4 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.2738C>G p.S913C 6:32210879-32210879 12
10 COSM6916495 MTOR soft tissue,retroperitoneum,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.4799A>G p.E1600G 1:11144721-11144721 12
11 COSM6986229 MDM2 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.865G>A p.A289T 12:68836696-68836696 12
12 COSM532 KRAS soft tissue,upper arm,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.38G>A p.G13D 12:25245347-25245347 12
13 COSM520 KRAS soft tissue,retroperitoneum,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.35G>T p.G12V 12:25245350-25245350 12
14 COSM6986226 KMT2A soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.3446G>C p.G1149A 11:118478078-118478078 12
15 COSM6986222 INPP4A soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.1621A>C p.I541L 2:98555592-98555592 12
16 COSM483 HRAS soft tissue,upper arm,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.35G>T p.G12V 11:534288-534288 12
17 COSM6928717 GREM1 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.404A>G p.E135G 15:32731094-32731094 12
18 COSM6920564 FLT3 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.1700A>G p.K567R 13:28034305-28034305 12
19 COSM6928367 FGFR1 soft tissue,lung,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.2149C>T p.H717Y 8:38414189-38414189 12
20 COSM6931170 FAT1 soft tissue,bone,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.9700G>A p.E3234K 4:186611539-186611539 12
21 COSM6931169 FAT1 soft tissue,bone,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.9700G>A p.E3234K 4:186611539-186611539 12
22 COSM6913537 ERBB2 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.584G>A p.C195Y 17:39709822-39709822 12
23 COSM6928364 EIF4E soft tissue,lung,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.346A>G p.T116A 4:98887132-98887132 12
24 COSM1583677 DDR2 soft tissue,lung,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.2125C>T p.R709* 1:162776212-162776212 12
25 COSM6931171 CTCF soft tissue,bone,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.1244G>A p.R415Q 16:67621478-67621478 12
26 COSM4283629 CIC soft tissue,lung,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.4613C>T p.P1538L 19:42294977-42294977 12
27 COSM6928370 CHEK2 soft tissue,lung,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.959A>G p.K320R 22:28699887-28699887 12
28 COSM6913117 CDK6 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.595C>G p.P199A 7:92671478-92671478 12
29 COSM6928718 CD276 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.353G>A p.G118D 15:73702528-73702528 12
30 COSM6986224 BRAF soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.325T>A p.F109I 7:140834788-140834788 12
31 COSM6916145 BCL6 soft tissue,lung,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.787G>A p.E263K 3:187729618-187729618 12
32 COSM6913121 ATRX soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.6106A>T p.K2036* 23:77593700-77593700 12
33 COSM4749459 soft tissue,lung,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.535C>A p.H179N 17:7675077-7675077 12
34 COSM326728 soft tissue,lung,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.535C>A p.H179N 17:7675077-7675077 12
35 COSM6933930 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.4456T>C p.S1486P 9:8317927-8317927 12
36 COSM326729 soft tissue,lung,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.139C>A p.H47N 17:7675077-7675077 12
37 COSM99617 soft tissue,bone,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.358C>T p.R120* 17:7674894-7674894 12
38 COSM99615 soft tissue,bone,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.637C>T p.R213* 17:7674894-7674894 12
39 COSM6928365 soft tissue,lung,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.2149C>T p.H717Y 8:38414189-38414189 12
40 COSM6986225 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.3446G>C p.G1149A 11:118478078-118478078 12
41 COSM6913538 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.539G>A p.C180Y 17:39709822-39709822 12
42 COSM4749460 soft tissue,lung,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.535C>A p.H179N 17:7675077-7675077 12
43 COSM1140133 soft tissue,retroperitoneum,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.35G>T p.G12V 12:25245350-25245350 12
44 COSM6986230 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.865G>A p.A289T 12:68836696-68836696 12
45 COSM6933926 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.5686T>C p.S1896P 9:8317927-8317927 12
46 COSM1645335 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.818G>A p.R273H 17:7673802-7673802 12
47 COSM6920562 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.168C>A p.Y56* 3:179198993-179198993 12
48 COSM99618 soft tissue,bone,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.637C>T p.R213* 17:7674894-7674894 12
49 COSM99616 soft tissue,bone,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.241C>T p.R81* 17:7674894-7674894 12
50 COSM6928369 soft tissue,lung,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.1088A>G p.K363R 22:28699887-28699887 12

Expression for Undifferentiated Pleomorphic Sarcoma

Search GEO for disease gene expression data for Undifferentiated Pleomorphic Sarcoma.

Pathways for Undifferentiated Pleomorphic Sarcoma

Pathways related to Undifferentiated Pleomorphic Sarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.6 IDH1 KIT KRAS MET PDGFRA PIK3CA
2
Show member pathways
13.33 CD74 KIT KRAS MET PDGFRA PIK3CA
3
Show member pathways
13.27 EZR KIT KRAS MET PDGFRA PIK3CA
4
Show member pathways
13.22 KIT KRAS MET PDGFRA PIK3CA STAT3
5
Show member pathways
12.92 KIT KRAS MET PDGFRA STAT3
6
Show member pathways
12.83 KIT KRAS MET PDGFRA PIK3CA
7
Show member pathways
12.8 KIT KRAS MET PDGFRA PIK3CA
8
Show member pathways
12.71 KRAS MET PDGFRA PIK3CA STAT3
9 12.67 KIT KRAS MET PDGFRA
10
Show member pathways
12.67 KIT KRAS MET PIK3CA
11
Show member pathways
12.67 KIT KRAS PDGFRA PIK3CA STAT3
12
Show member pathways
12.6 KRAS MET PIK3CA STAT3
13
Show member pathways
12.52 KRAS MET PDGFRA PIK3CA STAT3
14 12.5 EZR KRAS PDGFRA PIK3CA
15
Show member pathways
12.47 KIT KRAS MET PDGFRA PIK3CA
16
Show member pathways
12.46 KRAS PDGFRA PIK3CA STAT3
17 12.45 KIT KRAS MET PDGFRA PIK3CA STAT3
18
Show member pathways
12.44 KIT KRAS MET PDGFRA PIK3CA
19 12.43 CD74 KIT MLANA STAT3
20
Show member pathways
12.35 KRAS MET PDGFRA PIK3CA
21
Show member pathways
12.33 KRAS MET PIK3CA STAT3
22
Show member pathways
12.28 KRAS MET PDGFRA PIK3CA
23
Show member pathways
12.23 KIT KRAS PDGFRA PIK3CA
24
Show member pathways
12.14 KRAS MET PIK3CA STAT3
25 12.13 KRAS MET PIK3CA
26
Show member pathways
12.08 KIT PIK3CA STAT3
27
Show member pathways
12.07 KRAS PIK3CA STAT3
28 12.02 KIT MET PDGFRA
29
Show member pathways
12.01 EZR PIK3CA STAT3
30 11.98 KRAS PIK3CA STAT3
31
Show member pathways
11.98 KRAS PIK3CA STAT3
32 11.98 EZR KRAS MET MIR152 PDGFRA PIK3CA
33
Show member pathways
11.96 KRAS PIK3CA STAT3
34
Show member pathways
11.96 KRAS MET PIK3CA STAT3
35 11.95 KRAS PIK3CA STAT3
36
Show member pathways
11.93 KRAS MET PDGFRA
37 11.93 KRAS MET PDGFRA PIK3CA
38 11.86 EZR KRAS MET PIK3CA STAT3
39 11.8 KRAS PIK3CA STAT3
40
Show member pathways
11.8 KRAS PDGFRA PIK3CA STAT3
41 11.78 KRAS PIK3CA STAT3
42
Show member pathways
11.73 KRAS PIK3CA STAT3
43
Show member pathways
11.67 KIT KRAS PIK3CA
44
Show member pathways
11.17 MET PIK3CA STAT3
45 11.14 KRAS PIK3CA
46 11.1 PIK3CA STAT3
47 11.08 PDGFRA PIK3CA
48 11.05 PDGFRA PIK3CA
49 11.03 PDGFRA PIK3CA
50 10.91 IDH1 KIT KRAS MET PDGFRA PIK3CA

GO Terms for Undifferentiated Pleomorphic Sarcoma

Biological processes related to Undifferentiated Pleomorphic Sarcoma according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 9.95 KIT MET PDGFRA PIK3CA STAT3
2 positive regulation of gene expression GO:0010628 9.87 EZR KIT KRAS STAT3
3 negative regulation of apoptotic process GO:0043066 9.85 CD74 KIT MET PDGFRA STAT3
4 cytokine-mediated signaling pathway GO:0019221 9.84 KIT KRAS PIK3CA STAT3
5 MAPK cascade GO:0000165 9.8 KIT KRAS MET PDGFRA
6 peptidyl-tyrosine phosphorylation GO:0018108 9.77 KIT MET PDGFRA
7 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.75 KIT MET PDGFRA
8 negative regulation of signal transduction GO:0009968 9.73 KIT MET PDGFRA
9 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.73 CD74 KIT MET PDGFRA
10 liver development GO:0001889 9.7 KRAS MET PIK3CA
11 cell chemotaxis GO:0060326 9.65 KIT PDGFRA PIK3CA
12 positive regulation of protein kinase B signaling GO:0051897 9.62 KIT MET PDGFRA PIK3CA
13 female gonad development GO:0008585 9.59 IDH1 PDGFRA
14 2-oxoglutarate metabolic process GO:0006103 9.58 IDH1 IDH2
15 positive regulation of MAPK cascade GO:0043410 9.56 CD74 KIT MET PDGFRA
16 phosphatidylinositol-mediated signaling GO:0048015 9.54 EZR PDGFRA PIK3CA
17 positive regulation of phospholipase C activity GO:0010863 9.51 KIT PDGFRA
18 isocitrate metabolic process GO:0006102 9.4 IDH1 IDH2
19 phosphatidylinositol phosphorylation GO:0046854 9.26 KIT MET PDGFRA PIK3CA
20 glyoxylate cycle GO:0006097 9.16 IDH1 IDH2
21 positive regulation of kinase activity GO:0033674 8.92 CD74 KIT MET PDGFRA

Molecular functions related to Undifferentiated Pleomorphic Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.73 KIT KRAS MET PDGFRA
2 protein tyrosine kinase activity GO:0004713 9.65 KIT MET PDGFRA
3 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.58 KIT MET PDGFRA
4 MAP kinase kinase kinase activity GO:0004709 9.54 KIT MET PDGFRA
5 mitogen-activated protein kinase kinase binding GO:0031434 9.5 KIT MET PDGFRA
6 cytokine binding GO:0019955 9.46 CD74 KIT
7 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.43 KIT MET PDGFRA
8 isocitrate dehydrogenase activity GO:0004448 9.16 IDH1 IDH2
9 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.96 IDH1 IDH2
10 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 8.92 KIT MET PDGFRA PIK3CA

Sources for Undifferentiated Pleomorphic Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....